

Portal hypertension in acute liver failure

M Navasa, J C Garcia-Pagán, J Bosch, J R Riera, R Bañares, A Mas, M Bruguera, J Rodés

Abstract

Twenty five patients with acute liver failure were measured for hepatic venous pressure gradient as an index of portal pressure during the course of a transjugular liver biopsy. Hepatic venous pressure gradient ranged from 4 to 24.5 mm Hg with a mean of 12.8 (5.3) mm Hg (normal values <5 mm Hg). All patients but one had increased portal pressure gradient. Portal hypertension correlated with the degree of architectural distortion of the liver, as suggested by a direct correlation between hepatic venous pressure gradient and the area of reticulin collapse, evaluated by means of a morphometric analysis on Sirius red stained liver slides ($r=0.43$, $p<0.05$). Hepatic venous pressure gradient was significantly higher in patients with ascites (15.1 (5) mm Hg, $n=15$) or renal failure (14.4 (5.3) mm Hg, $n=16$) than in those without (9.3 (3.4) mm Hg and 10.1 (4) mm Hg, respectively; $p<0.05$). Portal hypertension was associated with systemic vasodilation and a hyperkinetic circulatory state, with decreased arterial pressure, and peripheral resistance and increased cardiac output.

Fulminant hepatic failure is a syndrome characterised by short term development of signs of advanced liver failure leading to hepatic encephalopathy in the absence of previous liver disease.¹ Fulminant hepatic failure has a very high mortality, especially when caused by acute viral hepatitis, which is the most common cause of this syndrome.^{1,2} Over half of the patients exhibit clinical signs associated with portal

hypertension, such as ascites and hepatorenal syndrome.^{3,4} It has been suggested that portal hypertension could be caused by an increased hepatic resistance to portal blood flow, as a consequence of sinusoidal collapse and distortion of liver architecture after extensive liver cell necrosis.^{3,5}

Transjugular liver biopsy allows histological and haemodynamic studies to be carried out during the course of fulminant hepatic failure.⁶ This allows better characterisation of portal hypertension and the examination of the relationship between portal pressure, presence of ascites and renal failure, and the extent of histological damage. This study presents our findings in a series of 25 consecutive patients.

Methods

PATIENTS

The study was carried out in 25 patients with acute liver failure admitted to the Liver Intensive Care Unit during a three year period. Fifteen patients were male and 10 female, with an age ranging from 14 to 62 years (mean (SD) 34 (15) years) (Table). The aetiology of liver failure was assessed by clinical history, and by serologic markers of hepatitis B, hepatitis delta, and hepatitis A. The possibility of Wilson's disease presenting as fulminant hepatic failure was investigated in all patients by measuring plasma and urine copper and plasma ceruloplasmin concentrations.

The diagnosis of acute liver failure was based on the accepted clinical criteria: development of

Liver Unit, Hospital Clinic i Provincial, University of Barcelona and Hospital Valle del Nalon, Riaño-Langreo, Asturias, Spain
M Navasa
J C Garcia-Pagán
J Bosch
J R Riera
R Bañares
A Mas
M Bruguera
J Rodés

Correspondence to:
J Bosch, Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic i Provincial, Villarroel 170, 08036 Barcelona, Spain.

Accepted for publication
21 October 1991

Clinical data of the 25 patients studied

Patient no	Age (yr)	Sex M/F	Aetiology	Ful/Sub	Enc (grade)	Ascites	Creat ($\mu\text{mol/l}$)	HVPG (mm Hg)	CO (l/min)	SVR (dyn/s.cm^{-5})	Death
1	40	M	D	Sub	IV	Yes	230	20.5	4	1800	Yes
2	16	F	D	Ful	II	No	71	8	-	-	No
3	39	M	nAnB	Ful	III	No	177	11	-	-	Yes
4	27	M	nAnB	Sub	IV	Yes	265	22	7.5	938	Yes
5	41	M	B	Sub	IV	Yes	972	16	8.9	952	Yes
6	51	M	nAnB	Sub	IV	Yes	804	14	-	-	Yes
7	24	M	nAnB	Ful	IV	No	221	6.5	13	369	Yes
8	22	M	D	Sub	IV	No	53	12.5	-	-	No
9	55	F	Haloth	Sub	II	Yes	53	12	8.1	829	No
10	62	M	A	Ful	IV	Yes	946	7	8.2	829	Yes
11	27	F	D	Sub	IV	Yes	354	14	-	-	Yes
12	22	M	B	Ful	IV	No	35	8	-	-	No
13	52	F	nAnB	Sub	IV	No	318	7	6.3	977	Yes
14	51	F	nAnB	Sub	IV	Yes	557	24.5	6.4	1375	Yes
15	23	F	D	Sub	IV	Yes	97	9	-	-	Yes
16	62	M	B	Sub	IV	Yes	610	18	-	-	Yes
17	42	F	nAnB	Sub	IV	No	132	15	-	-	Yes
18	21	M	D	Sub	II	Yes	97	18	-	-	No
19	24	F	B	Ful	II	No	53	7.5	-	-	No
20	23	M	D	Sub	IV	Yes	919	16.5	6.5	1070	Yes
21	14	F	nAnB	Sub	II	Yes	132	12	6.2	1058	No
22	25	M	nAnB	Sub	IV	No	857	13	13	363	Yes
23	43	M	B	Ful	IV	Yes	185	9	-	-	Yes
24	21	M	D	Ful	IV	Yes	238	15	8.4	971	No
25	26	F	B	Ful	IV	No	132	4	5.5	1381	Yes

Ful/Sub: fulminant/subfulminant; Enc: encephalopathy; Creat: creatinine; HVPG: hepatic venous pressure gradient; CO cardiac output; SVR: systemic vascular resistance; M/F: male/female; D: virus delta hepatitis; nAnB: virus non-A non-B hepatitis; B: virus B hepatitis; Haloth: halothane hepatitis; A: virus A hepatitis.

hepatic encephalopathy and fall in prothrombin index below 40% within eight weeks of the onset of symptoms in the absence of previous liver disease.¹ Patients were divided in two groups: (i) fulminant hepatic failure, when hepatic encephalopathy appeared in less than two weeks after the onset of jaundice, and (ii) subfulminant hepatic failure if hepatic encephalopathy complicated liver failure two to eight weeks after the onset of jaundice.¹

After admission, the patients were transferred to the Liver Intensive Care Unit. Physical examination including the presence or development of ascites and evaluation of neurological status were performed at least every four hours. All patients had continuous monitoring of arterial pressure and urine output. Biochemical analysis including standard liver and renal function tests, as performed daily until death or recovery. Renal failure was considered to be present when plasma creatinine increased above 132 $\mu\text{mol/l}$.

Within 48 hours of admission, all patients underwent a haemodynamic study during transjugular liver biopsy. Briefly, under local anaesthesia a venous introducer (USCI International Inc, Mass, USA) was placed in the right internal jugular vein by the Seldinger technique, and the main right hepatic vein was catheterised under fluoroscopy using a 7F balloon tipped catheter (Medi-Tech, Cooper Scientific Corp, Watertown, MA, USA); repeated measurements of wedged and free hepatic venous pressures were obtained by inflating and releasing the balloon. Portal pressure was estimated from the hepatic venous pressure gradient – that is, the difference between wedged hepatic venous pressure and free hepatic venous pressure.⁷ In 13 of these patients a Swan-Ganz catheter was inserted into the pulmonary artery for measurements of cardiopulmonary pressures and cardiac output (Edwards Laboratory, Los Angeles, CA, USA) (thermal dilution). Arterial pressure was monitored by sphygmomanometry (Dinamap, Critikon, Tampa, Florida, USA) and heart rate recorded by continuous electrocardiograph monitoring. Systemic vascular resistance ($\text{dyn}/\text{sec}\cdot\text{cm}^{-5}$) was calculated as $(\text{MAP}-\text{RAP})\cdot 80/\text{CO}$, in which MAP is the mean arterial pressure, RAP is the right atrial pressure, and CO the cardiac output. All measurements were performed by triplicate and permanent tracings were obtained on a multichannel recorder (Hewlett Packard 7754B). After that, an 8 F catheter was introduced in the hepatic vein and a preshaped liver biopsy needle (Ingenor Medical, Paris, France) was slipped into the catheter and the transjugular liver biopsy was obtained in each patient using the standard technique.⁶ There were no complications from these procedures.

Liver biopsy specimens were sectioned serially and stained with haematoxylin and eosin, Masson's trichrome stain, and reticulin stain for conventional histological analysis. In addition, all specimens were stained with Sirius red F3BA in order to do a quantitative morphometric analysis of the reticulin collapse by means of an automatic image quantifier (Ramtek-9351), as previously described.^{8,9} The measurements were based on the contrast between dark (collapse)

and light areas. Three consecutive liver areas were evaluated for each specimen by one of us, under blind conditions. The results were expressed as the mean percentage of Sirius red stained area of the section. The intra assay variability of the measurement was of 6%.

STATISTICAL ANALYSIS

All values are reported as mean (SD). The Student's *t* test, the χ^2 test and the coefficient of correlation were used in the statistical analysis of the results. Statistical significance was established at $p < 0.05$.

Results

The mean time between the onset of clinical symptoms and the haemodynamic study was 21 days, with a range of six to 56 days. The course of liver failure was subfulminant in 16 patients (64%) and fulminant in the remaining nine patients.

The aetiology of acute liver failure was viral hepatitis in all but one patients. Six patients had acute hepatitis B (24%), eight acute delta infection (32%), one had hepatitis A (4%), one had halothane hepatitis and the remaining nine cases were considered as non-A-non-B hepatitis (36%) (Table). Ascites was detected in 15 patients (60%). The ascites had a low protein content (14 (6) g/l). Renal failure developed in 16 (64%).

As shown in the Table, hepatic venous pressure gradient ranged from 4 to 24.5 mm Hg with a mean of 12.8 (5.3) mm Hg (normal values < 5 mm Hg) (Fig 1). All patients but one had an increased hepatic venous pressure gradient. Fifteen patients (60%) had a hepatic venous pressure gradient equal or greater than 12 mm Hg, and were considered to have severe portal hypertension, while nine patients had minor degrees of portal hypertension (hepatic venous pressure gradient from 6 to 11 mm Hg). The 13 patients who had measurements of cardiac output, showed a hyperdynamic circulation manifested by a high cardiac output (7.8 (2.6) l/min), and decreased mean arterial pressure (89 (16) mm Hg) and systemic vascular resistance (993 (387) $\text{dyn}/\text{sec}\cdot\text{cm}^{-5}$).

Presence of ascites was related to the severity of portal hypertension. The hepatic venous pressure gradient was significantly higher in patients with ascites (15.1 (5) mm Hg) than in those without (9.3 (3.4) mm Hg), ($p < 0.01$). Moreover, among the 15 patients with ascites, 12 (80%) had severe portal hypertension. On the contrary, only three of the 10 patients without ascites had an hepatic venous pressure gradient above 12 mm Hg ($p < 0.02$).

Patients with renal failure had a higher hepatic venous pressure gradient than those without it (14.4 (5.3) mm Hg *v* 10.1 (4) mm Hg, respectively; $p < 0.05$). Renal failure was present in 11 of the 15 patients with an hepatic venous pressure gradient above 12 mm Hg.

The hepatic venous pressure gradient was significantly higher in patients with subfulminant hepatic failure (15.3 (4.6) mm Hg) than in those with fulminant hepatic failure (8.4 (3.1)




Figure 1: Individual values of the hepatic venous pressure gradient (HVPg) in patients with acute liver failure. The horizontal line indicates the mean value of the whole series. Patients with fulminant liver failure are represented by squares, while those with subfulminant (over two weeks course) are represented by circles. Note that the latter had a greater HVPg than the former (15.3 (4.6) v 8.4 (3.1) mm Hg, respectively). The shadowed area represent the normal range.

mm Hg, $p < 0.001$). Among the 16 patients with subfulminant hepatic failure, all but two (87.5%) had an hepatic venous pressure gradient above 12 mm Hg. This was only seen in one of the nine patients with fulminant hepatic failure ($p < 0.001$) (Table). Ascites was more common in patients with subfulminant hepatic failure than in patients with fulminant hepatic failure (12/16 v three of nine patients, respectively, $p = 0.08$).

Reticulin collapse, measured by the percentage of the total area of the section stained by Sirius red averaged 15.7 (8.4)% (mean value in normal liver 3.1 (0.5)%).⁹ There was a direct correlation between the degree of reticulin collapse and the hepatic venous pressure gradient ($r = 0.43$, $p < 0.05$) (Fig 2).

There were no significant differences in the degree of collapse between patients with fulminant and subfulminant hepatic failure (14.6 (9.0) v 16.2 (8.3)%, NS).

The whole mortality rate of the present series was 68%. There were no significant differences in hepatic venous pressure gradient between patients who survived and those who did not (11.6 (3.7) v 13.3 (5.9) mm Hg, NS). The area of reticulin collapse, however, was significantly lower in survivors (9.7 (4.7) v 18.1 (8.3)%, $p < 0.02$).




Figure 2: Correlation between the area of reticulin collapse (as the percentage of the total area of the biopsy slide stained by Sirius red) and the hepatic venous pressure gradient (HVPg).

Discussion

Portal hypertension usually complicates the evolution of chronic liver diseases.¹⁰ Ascites and gastrointestinal bleeding caused by ruptured oesophageal varices are frequent consequences of severe portal hypertension.¹¹ It has been shown that the development of ascites is also common in acute liver failure,^{3,4} and has been related to the presence of severe portal hypertension.^{3,5} Previous studies from our unit, however, have shown that ascites may occur in patients with acute viral hepatitis in the absence of portal hypertension.¹² These patients exhibited an 'exudative' ascites with a high protein and lymphocyte content and had a good prognosis.¹²

The present study further shows that portal hypertension is common in acute liver failure. In fact, all but one of the patients studied had a hepatic venous pressure gradient above the normal values, thus indicating intrahepatic sinusoidal portal hypertension.¹⁰ Although portal pressure is determined by the interrelationship of blood flow and vascular resistance, it is generally accepted that portal hypertension is initiated by an increased resistance to portal blood flow.^{10,13} The site of increased resistance in patients with acute liver failure has not been clearly established. There is no evidence of sinusoidal fibrosis and nodular regeneration.¹⁴ Similarly, there is no massive infiltration of the liver, as happens in portal hypertension that may be associated with haematologic disorders or amyloidosis,¹⁵ nor evidence of obstruction at the hepatic outflow, as observed in venoocclusive disease.¹⁶ Therefore, the most likely explanation for the increased hepatic venous pressure gradient is the extensive necrosis and subsequent reticulin collapse, that probably causes a severe distortion of the hepatic microcirculation. The direct correlation found in the present study between the degree of reticulin collapse and the hepatic venous pressure gradient, which is very similar to that obtained by Valla *et al*⁵ in patients with acute viral hepatitis, further supports this hypothesis. The correlation between the area of reticulin collapse, however, and hepatic venous pressure gradient, although statistically significant, was poor. This may indicate that other factors also play an important role in increasing hepatic venous pressure gradient in acute liver failure. In addition, it is likely that morphometric analysis in the transjugular biopsies is subject to some degree of sampling error, which may obscure this relationship. Measurements of hepatic venous pressure gradient with the balloon occlusion technique, however, estimate the sinusoidal perfusion pressure in a relatively large area of the liver.¹⁷ It is therefore possible that measurements of hepatic venous pressure gradient provide a better estimate of the degree of architectural distortion in acute liver failure than morphometric analysis of liver biopsies. Nevertheless, the current finding of a statistically significant greater degree of reticulin collapse in patients who died than in the survivors clearly points out the important prognostic connotation of the severity of histological damage in patients with acute liver failure.¹⁸

The present study also shows a high prevalence of ascites in patients with acute liver failure.

Our data and previous studies^{3,5} indicate that the presence of ascites is related to the magnitude of the increase in portal pressure. This would suggest that, as in cirrhosis,¹⁹ portal hypertension plays an important role in the pathogenesis of ascites in acute liver failure.

It is important to note that patients with acute liver failure showed a hyperdynamic circulation, evidenced by a high cardiac output and decreased systemic vascular resistances and mean arterial pressure. This vasodilatation is thought to be the mechanism triggering the activation of neuro-humoral factors contributing to sodium retention, extracellular fluid volume expansion and ascites formation.¹⁹ In addition, splanchnic vasodilation, which results in increased portal inflow, may contribute to increase portal pressure, specially when the hepatic vascular resistance is increased.¹⁰ The pathogenesis of systemic vasodilation remains largely conjectural. As suggested in patients with cirrhosis, it is likely to be of multifactorial origin.^{10,19} A possible explanation is the accumulation of vasoactive substances of splanchnic origin in the systemic circulation that are either metabolised by the normal liver or abnormally released during acute liver failure.^{10,20,21} In that regard it has been reported that increased levels of substance P are observed in patients with advanced liver failure and that these correlate with the degree of hypotension.²² In addition, other factors such as endotoxaemia, sepsis, and fever may contribute to further exaggerate these circulatory abnormalities.²¹

Renal failure was common in the present series of patients with acute liver failure. Some of these patients had acute tubular necrosis, which may be related to shock, bacteraemia hypovolaemia and drug nephrotoxicity. Some patients, however, exhibited 'functional' renal failure, with many similarities observed in cirrhosis. As in this condition,²³ functional renal failure in acute liver failure has been related to an imbalance between neurohumoral factors with renal vasoconstrictive activity and renal vasodilators.²⁴ In this regard, increased plasma renin activity and decreased renal prostaglandin production have been reported in patients with acute liver failure.²⁴ As already mentioned, activation of neurohumoral vasoactive factors is triggered by the extreme vasodilation frequently seen in these patients.¹⁹ Therefore, as in cirrhotics with hepatorenal syndrome, patients with acute liver and renal failure exhibit renal vasoconstriction in the context of marked systemic vasodilation. This indicates that there should be some areas where vasodilation is greater than others. Experimental data suggest that vasodilation predominates in the splanchnic territory.²⁵ It is thus possible that if the splanchnic vasodilation could be overcome, there could be an amelioration in the systemic and renal circulation.²⁶ This actually has been reported in patients with cirrhosis,²⁷ Although there has not yet been a clinical or experimental study exploring this possibility in acute liver failure.

Finally, it should be emphasised that we had no complications in obtaining transjugular biopsies in patients with acute liver failure despite the severe coagulopathy inherent to this condition, even though these studies were frequently

carried out in comatosed patients. Our findings indicate that the combined histological haemodynamic evaluation provided by this procedure may help to optimise the medical management of these critically ill patients.

We are indebted to Angels Baringo for his expert assistance in these studies and to Lidia París and Eulàlia Ventura for secretarial support. Supported in part by grants from the Fundació Catalana per a l'Estudi de les Malalties del Fetge. Dr J C Garcia-Pagán held a research fellowship from Fondo de Investigaciones Sanitarias de la Seguridad Social (FISS-89/1516).

- Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. *Semin Liver Dis* 1986; 6: 97-106.
- Tygstrup N, Ranek L. Assessment of prognosis in fulminant hepatic failure. *Semin Liver Dis* 1986; 6: 129-37.
- Lebrec D, Nouel O, Bernuau J, Rueff B, Benhamou JP. Portal hypertension in fulminant viral hepatitis. *Gut* 1980; 21: 962-4.
- Navasa M, Panés J, Terés J, Bruguera M, Rodés J. Insuficiencia hepática aguda grave: análisis de 51 casos. *Gastroenterol Hepatol* 1986; 9: 221-7.
- Valla D, Flejou JF, Lebrec D, Bernuau J, Rueff B, Salzmann JL, et al. Portal hypertension and ascites in acute hepatitis: Clinical, hemodynamic and histological correlations. *Hepatology* 1989; 10: 482-7.
- Lebrec D, Goldfarb G, Degott C, Rueff B, Benhamou JP. Transvenous liver biopsy. An experience based on 1000 hepatic tissue samplings with this procedure. *Gastroenterology* 1982; 83: 338-40.
- Bosch J, Mastai R, Kravetz D, Navasa M, Rodés J. Hemodynamic evaluation of the patient with portal hypertension. *Semin Liver Dis* 1986; 6: 309-17.
- Sweat F, Fuchter H, Rosenthal SI. Sirius red F3BA as a stain for connective tissue. *Arch Pathol* 1964; 78: 69-72.
- Rubio CA, Porwit A. Quantitation of fibrosis in liver biopsies. *Anal Quant Cytol Histol* 1988; 10: 107-9.
- Bosch J, Navasa M, Garcia-Pagán JC, DeLacy AM, Rodés J. Portal Hypertension. *Med Clin North Am* 1989; 73: 931-53.
- García-Tsao G, Groszmann RJ, Fisher RL, Conn H, Atterbury E, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. *Hepatology* 1985; 5: 419-24.
- Viola C, Vineta L, Bosch J, Rodés J. Exudative ascites in the course of acute type B hepatitis. *Hepatology* 1983; 3: 1013-5.
- Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. *Am J Physiol* 1985; 248: G618-25.
- Anthony PP, Oshak KG, Nayac NC. The morphology of cirrhosis. *J Clin Pathol* 1978; 31: 395-414.
- Urbano A, Navasa M, Mont LI, Bosch J, Bruguera M, Rodés J. Colestasis intrahepática e hipertensión portal en un paciente con amiloidosis primaria. *Gastroenterol Hepatol* 1986; 9: 186-8.
- Kasturi TE, Manchanda SC, Tandon RK, Rajani M, Bathia ML. Haemodynamic studies in veno-occlusive disease of the liver. *Br Heart J* 1979; 41: 594-9.
- Groszmann RJ, Glickman M, Blei AT, Storer E, Conn HO. Wedged and free hepatic venous pressure measured with a balloon catheter. *Gastroenterology* 1979; 76: 253-8.
- Gazzard BG, Portmann B, Murray-Lyon IM, Williams R. Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage. *Q J Med* 1975; 176: 615-26.
- Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. *Hepatology* 1988; 8: 1151-7.
- Bihari DJ, Gimson AES, Williams R. Cardiovascular, pulmonary and renal complications of fulminant hepatic failure. *Semin Liver Dis* 1986; 6: 119-28.
- Trewby PN, Williams R. Pathophysiology of hypotension in patients with fulminant hepatic failure. *Gut* 1977; 18: 1021-6.
- Hörtnagl H, Lochs H, Kleinberger G, Singer EA, Lenz K. Substance P is markedly increased in plasma of patients with hepatic coma. *Lancet* 1984; i: 480-3.
- Ring-Larsen H, Henriksen JH. Pathogenesis of ascites formation and hepatorenal syndrome: Humoral and hemodynamic factors. *Semin Liver Dis* 1986; 6: 341-52.
- Guarner F, Hughes RD, Gimson AES, Williams R. Renal function in fulminant hepatic failure: haemodynamics and renal prostaglandins. *Gut* 1987; 28: 1643-7.
- Fernandez-Seara J, Prieto J, Quiroga J, Zozaya JM, Cobos MA, Rodriquéire JL et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. *Gastroenterology* 1989; 97: 1304-12.
- Bosch J. Splanchnic vasodilation and renal vasoconstriction: A key to the hepatorenal syndrome? *Hepatology* 1990; 12: 1445-7.
- Lenz K, Hortnagle H, Druml W, Grimm G, Laggner A, Schneeweis B, et al. Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis. *Gut* 1989; 30: 90-6.



Portal hypertension in acute liver failure.

M Navasa, J C Garcia-Pagán, J Bosch, et al.

Gut 1992 33: 965-968

doi: 10.1136/gut.33.7.965

Updated information and services can be found at:

<http://gut.bmj.com/content/33/7/965>

These include:

References

Article cited in:

<http://gut.bmj.com/content/33/7/965#related-urls>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>